Evidence map›Paper›PMID 37020549›Full record

ArticleFrontiers in immunology2023

Hormonal and inflammatory modulatory effects of hesperidin in hyperthyroidism-modeled rats.

Mahmoud Ashry, Hussam Askar, Manar M Obiedallah, Ahmed Hussuin Elankily, Doaa Galal El-Sahra, Gamal Zayed, Mohamed A Mustafa, Sawsan Abd El-Maksoud El-Shamy, Somaia A Negm, Marwa A El-Beltagy and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. International journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Mahmoud AshryZoology Department, Faculty of Science, Al-Azhar University, Assiut, Egypt.
Hussam AskarZoology Department, Faculty of Science, Al-Azhar University, Assiut, Egypt.
Manar M ObiedallahInstitute of Chemical Technology, Ural Federal University, Ekaterinburg, Russia.
Ahmed Hussuin ElankilyZoology Department, Faculty of Science, Al-Azhar University, Assiut, Egypt.
Doaa Galal El-SahraMedical Surgical Nursing Department, Faculty of Nursing, Modern University for Technology and Information, Cairo, Egypt.
Gamal ZayedDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Mohamed A MustafaBasic Centre of Science, Misr University for Science and Technology, Giza, Egypt.
Sawsan Abd El-Maksoud El-ShamyBiology Department, Basic Centre of Science, Misr University for Science and Technology, Giza, Egypt.
Somaia A NegmFaculty of Applied Health Science Technology, Misr University for Science and Technology, Giza, Egypt.
Marwa A El-BeltagyBiochemistry Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.
Khaled G Abdel-WahhabMedical Physiology Department, National Research Centre, Giza, Egypt.
Antoaneta EneINPOLDE Research Center, Department of Chemistry, Physics and Environment, Faculty of Sciences and Environment, Dunarea de Jos University of Galati, Galati, Romania.
Al-Azhar University · EGMisr University for Science and Technology · EG"Dunarea de Jos" University of Galati · ROModern University for Information and Technology · EGNational Research Centre · EGSuez Canal University · EGUral Federal University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of the current study was to investigate the hormonal modulatory efficiency of hesperidin, through its regulatory potential of immunological, inflammatory, and/or antioxidant changes in on hyperthyroidism modeled adult female albino rats. Both normal and hyperthyroidism modeled rats (140-160g) were randomly divided into four groups (10 animals each) as follows: 1) healthy animals were daily ingested with saline for six weeks, and served as control group, 2) healthy animals were intraperitoneally injected with hesperidin (50 mg/kg/day) for a similar period, 3) hyperthyroidism-modeled animals without any treatment acted as positive control, and 4) hyperthyroidism-modeled animals were treated intraperitoneally with hesperidin for a similar period. The findings showed that hesperidin significantly modulated hyperthyroidism deteriorations, this was evidenced by a remarkable decline in serum T4, FT4, T3, FT3, TNF-α, IL1β-, IL4-, IL-6, and IL-10 levels, with a minor increase in TSH and significant raise in CD4+ level. Similarly, valuable improvement was observed in the oxidative status; serum SOD, GPx, CAT, and GSH levels were dramatically enhanced, associated with remarkable drop in MDA and NO levels. Also, hesperidin demonstrated nephro-hepatoprotective and anti-atherogenic potential, this was achieved from the notable reduction in ALAT and ASAT activities as well as urea, creatinine, cholesterol, and triglyceride close to the corresponding values of healthy group. These findings were supported by histological and immunohistochemical ones that showed a notable decrease in the expression of the calcitonin antibody. In conclusion, hesperidin possesses anti-hyperthyroidism, immunoinflammatory regulatory, and antioxidant activities that evidenced from the improvement of physio-architecture of the thyroid gland, reduction of inflammation and restoration of the impaired oxidative stress. This effect might be mechanized through immunological, inflammatory, apoptotic, and/or antioxidant modulatory pathways.

Indexed as

HesperidinHyperthyroidismAnimalsAntioxidantsFemaleOxidative StressRatsSuperoxide DismutaseAntioxidantsHesperidinSuperoxide Dismutaseanti-inflammatoryhesperidinhyperthyroidismL-Thyroxinerat

Identifiers

PMID37020549
PMCPMC10067561
OpenAlexW4327933920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.